

One-pot hydrosilylation–protodesilylation of functionalized diarylalkynes: a highly selective access to *Z*-stilbenes. Application to the synthesis of combretastatin A-4

Anne Giraud^a, Olivier Provot^{a,b,*}, Abdallah Hamzé^{a,b}, Jean-Daniel Brion^{a,b},
Mouâd Alami^{a,b,*}

^a Univ Paris-Sud, BioCIS, UMR 8076, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie,
rue J.B. Clément, Châtenay-Malabry F-92296, France

^b CNRS, BioCIS, UMR 8076, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie, rue J.B. Clément, Châtenay-Malabry F-92296, France

Received 16 November 2007; revised 10 December 2007; accepted 12 December 2007

Available online 8 January 2008

Abstract


An efficient stereoselective synthesis of *Z*-stilbenes has been developed from diarylalkynes via a new hydrosilylation–protodesilylation process. The scope and limitation of this method is presented to stereoselectively prepare a wide range of (*Z*)-stilbenes in a one-pot way is presented. A concise application to the preparation of combretastatin A-4 (**CA-4**), a vascular targeting agent inhibitor of tubulin polymerisation is described.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Combretastatin A-4; (*Z*)-Stilbenes; Hydrosilylation; Desilylation; Platinum

A large number of stilbene (1,2-diphenylethylene) derivatives have been isolated from various plant species and exhibit a large panel of biological activities such as, anti-neoplastic, antiangiogenesis, cytotoxic and inhibition of cell proliferation.¹ Beside *trans* stilbene derivatives and one of their leader, resveratrol, a large number of their *cis* homologues were isolated, synthesized and evaluated. The most promising of these stilbenes thus far are combretastatins and particularly the combretastatin A-4 (**CA-4**) due to its biological activities combined to its structural simplicity (Scheme 1).²

If the access of *trans* stilbenes is well documented,³ there are only few methodologies that give access to their *cis* counterparts. The most popular approach is based on the *Z* selective-Lindlar⁴ semi-reduction of diarylalkynes but it suffers from several drawbacks as (*Z*) to (*E*) isomerization,



Scheme 1.

overreduction to the alkane making purifications tedious and problems with reproducibility.

As a part of our research devoted to anticancer agents⁵ which target tubulin,⁶ we wished to synthesize the natural product **CA-4** as a reference molecule since, to our knowledge, **CA-4** is not commercially available anymore. The chemical synthesis of **CA-4** has been tackled in a variety of ways.^{1b,7} While these reactions are suitable methods, many of them either display low stereoselectivity or do not tolerate sensitive functionalities. Therefore, alternative routes for the synthesis of **CA-4** are welcome. A recent

* Corresponding authors. Tel.: +33 1 46835847; fax: +33 1 46835828 (O.P.).

E-mail addresses: olivier.provot@u-psud.fr (O. Provot), mouad.alami@u-psud.fr (M. Alami).


work describing the synthesis of **CA-4** and analogues by hydrolysis of Ti(II)–alkynes complexes⁸ prompted us to publish our preliminary results in the *Z*-semi-reduction of alkynes field.

Recently, we showed that heterogeneous platinum oxide (PtO₂) is a very efficient catalyst for the hydrosilylation of *para* and *ortho* substituted diarylalkynes. The H–Si bond addition proceeds in a stereoselective *cis*-fashion⁹ and the regioselectivity of the reaction was found to be governed by *ortho*-directing effects (ODE)¹⁰ rather than the nature of the platinum catalysts. We reasoned that this efficient hydrosilylation of internal arylalkynes could be efficiently exploited to give, after linkage of the C–Si bond, *Z*-stilbenes of high biological interest. We present in this communication a convenient one-pot procedure for the *Z*-selective semi-reduction of diarylalkynes via a hydrosilylation–protodesilylation sequence.

To define optimal reaction conditions, we have studied initially the hydrosilylation of diarylalkynes **1a** and **1b** as model substrates and their subsequent desilylation. The results are summarized in Table 1. Preliminary experiment was carried out using HSiEt₃ (1.5 equiv), PtO₂ (7 mol %) at 60 °C in the absence of solvent as we previously reported.⁹ In this case, a mixture of vinylsilanes was obtained in a quantitative yield after purification on silica gel. However, the desilylation of the vinylsilanes mixture using TBAF (1.5 equiv) at 60 °C afforded a moderate yield of *Z*-**3a** together with significant amounts of *E*-**3a** (entry 1). A survey of the sequence hydrosilylation–protodesilylation sequence of alkyne **1a** under the same conditions in the

presence of other representative silanes, including HSiPh₂Me, HSi(OEt)₃ and HSiOEtMe₂ was conducted (entries 2–4). In these cases, we were pleased to observe the formation of a single *Z*-**3a** stereoisomer whatever the nature of the silane used and the better overall yield was obtained with the non-toxic¹¹ HSiOEtMe₂ (77% for the two steps, entry 4). Encouraged by this result, the effect of PtCl₄, PtCl₂ and Pt/C on the outcome of the hydrosilylation reaction was investigated. None of these platinum catalysts led to better results than those achieved with PtO₂ (entries 5–7). One can note that H₂PtCl₆ (Speier's catalyst), which is considered to be the catalyst of choice for *cis*-hydrosilylation of internal alkynes,¹² was not efficient and led to a complex mixture (entry 7). Having defined the best conditions [PtO₂ (7 mol %), HSiOEtMe₂ (1.5 equiv), 60 °C then TBAF (1.5 equiv), 0 °C] *Z*-stilbene **3b** bearing a 3,4,5-trimethoxyaryl moiety was prepared and isolated in good yield (entry 9). Careful inspection of the ¹H NMR spectrum of the crude reaction mixture indicated that the stilbene **3b** was formed in a 98:2/*Z*:*E* ratio. A similar result was obtained when using HSi(OEt)₃ instead of HSiOEtMe₂ (entry 10). Finally, the best result in terms of yield and *Z*-stereoselectivity was observed when the desilylation step of vinylsilane **2b-4** was achieved at room temperature (entry 11). In this case, *Z*-stilbene **3b** was obtained as a single *Z* stereoisomer in a 77% overall isolated yield (based on alkyne **1b**). We then applied this two stage process to prepare the target natural product **CA-4**¹³ from diarylalkyne **1c**. We were delighted to observe that the hydrosilylation–protodesilylation proceeded

Table 1
Hydrosilylation–protodesilylation sequence; access to *Z*-stilbenes **3**



Entry	Diarylalkyne 1	H-[Si]	Catalyst	Yield ^a of 2 ^b (%)	Yield ^a of 3 (%)	<i>Z</i> / <i>E</i> ratio ^c
1	1a R = 4-OMe, R ¹ = H	1: HSiEt ₃	PtO ₂	2a-1 97	3a 58	85/15
2	1a R = 4-OMe, R ¹ = H	2: HSiPh ₂ Me	PtO ₂	2a-2 93	3a 49	100/0
3	1a R = 4-OMe, R ¹ = H	3: HSi(OEt) ₃	PtO ₂	2a-3 70	3a 80	100/0
4	1a R = 4-OMe, R ¹ = H	4: HSiOEtMe ₂	PtO ₂	2a-4 86	3a 90	100/0
5	1a R = 4-OMe, R ¹ = H	4: HSiOEtMe ₂	PtCl ₂	2a-4 44	3a nd ^d	nd ^d
6	1a R = 4-OMe, R ¹ = H	4: HSiOEtMe ₂	Pt/C	2a-4 38	3a —	—
7	1a R = 4-OMe, R ¹ = H	4: HSiOEtMe ₂	PtCl ₄	2a-4 56	3a —	—
8	1a R = 4-OMe, R ¹ = H	4: HSiOEtMe ₂	H ₂ PtCl ₆	2a-4 Mixture	3a —	—
9	1b R = 2,3,4-OMe, R ¹ = H	4: HSiOEtMe ₂	PtO ₂	2b-4 87	3b 77	98/2
10	1b R = 2,3,4-OMe, R ¹ = H	3: HSi(OEt) ₃	PtO ₂	2b-3 78	3b 84	98/2
11	1b R = 2,3,4-OMe, R ¹ = H	4: HSiOEtMe ₂	PtO ₂	2b-4 87	3b 88 ^e	100/0
12	1c R = 2,3,4-OMe, R ¹ = 3-OH, 4-OMe	4: HSiOEtMe ₂	PtO ₂	2c-4 70 ^f	CA-4 69	100/0

^a Isolated yield.

^b Mixture of regioisomers (ratio not determined).

^c *Z*:*E* Ratios quoted as a percentage composition of total yield as estimated from ¹H NMR spectra.

^d Not determined.

^e Protodesilylation was achieved at rt.

^f 4 equiv of HSiOEtMe₂ were required.

Table 2
One-pot access to *Z*-stilbenes **3** from diarylalkynes **1**















Entry	Alkynes	Stilbenes	Z/E Ratio ^a	Yield ^b
1	1a		3a 100/0	77
2	1d		3d 100/0	90
3	1e		3e 100/0	75
4	1f		3f 100/0	51
5	1g		3g 100/0	49 ^c
6	1h		3h 100/0	65
7	1i		3i 100/0	79
8	1j		3j >95/5	51
9	1k		3k 100/0	95
10	1l		3l >95/5	62
11	1m		3m >95/5	75
12	1n		3n 90/10	73

Table 2 (continued)

Entry	Alkynes	Stilbenes	Z/E Ratio ^a	Yield ^b
13	1o		3o 88/12	78
14	1c		CA-4 90/10	67

^a *Z*:*E* Ratios quoted as a percentage composition of total yield as estimated from ¹H NMR spectra.

^b Isolated yield.

^c Unoptimized yield.

extremely efficiently to give the desired **CA-4** as a single *Z*-isomer in good yield (entry 12).

From a practical point of view of the synthetic chemist, we explored the process in a one-pot manner. Thus, after the hydrosilylation step, the excess of the volatile HSiOEtMe₂ was removed to achieve the protodesilylation step with TBAF (3 equiv) at 0 °C for a better *Z*-stereoselectivity. Scope and limitations of this one-pot process using various functionalized diarylalkynes **1** are summarized in Table 2.

Diarylalkynes **1a**, **1d–f** substituted with an electron donating group (OMe, Me) have been transformed successfully into their corresponding stilbenes **3** in good yields (entries 1–4). It should be noted that the position of the substituent on the aromatic ring had no influence on the *Z*-stereochemistry of the stilbenes formed (entries 1–3). A similar result (total *Z*-stereocontrol) has been obtained from **1g** bearing a pivaloyl ester function but with a moderate unoptimized 49% yield (entry 5). We were also pleased to observe that halogenated substituted arylalkynes **1h** and **1i** afforded the expected stilbenes **3h** and **3i**, respectively, in acceptable yields and again as single *Z*-stereoisomers (entries 6 and 7). When the push–pull diarylalkynes **1j** was employed as a substrate, it was found that the *Z*-stereochemistry of this one-pot process was slightly reduced. In this case, traces of the *E*-stilbene were detected by ¹H NMR spectroscopy. This PtO₂-catalyzed hydrosilylation–protodesilylation one-pot process can be performed also with alkyne **1k** bearing a methoxycarbonyl group as illustrated in entry 9. In this case again a total *Z*-stereochemistry associated with a nearly quantitative yield was observed (95%).

We next embarked on the utilization of this process for the conversion of 3,4,5-trimethoxyarylalkynes to their corresponding *Z*-stilbenes, analogues of **CA-4**. Starting from 3,4,5-trimethoxyarylalkynes **1l** and **1m** bearing an ortho or a para methoxy group, respectively, it was noted that the 3,4,5-trimethoxyaryl unit smoothly affected the *Z*-stereoselectivity (>95%, entries 10 and 11) providing **3l**

and **3m**¹⁴ in good yields. Similarly, we succeeded in the one-pot preparation of known biologically active analogues of **CA-4**, **3n**¹⁵ and **3o**¹⁶ in good yields and high *Z*-stereocontrol (entries 12 and 13).

On account of the large scope of this one-pot procedure, we then attempted to synthesize **CA-4** from the corresponding **1c** having a free phenolic function. Because of the side silylation of the phenol moiety, the desilylation step was conducted at 60 °C. As shown in entry 14, **CA-4** was obtained with fortunately an excellent *Z*-stereoselectivity (*Z*:*E*/90:10) and in a good yield. Careful separation on silica gel afforded pure **CA-4**, which could be used as reference for biological evaluation of analogues that would be reported in due course.

In summary, we have developed a new, mild and efficient method for the synthesis of *Z*-stilbenes from diarylalkynes. This method is complementary to the existing procedures and sometimes could be the method of choice because of its chemoselectivity, simplicity and its excellent *Z*-stereoselectivity. The ease by which several *Z*-stilbenes were obtained with a total *Z*-stereocontrol and in good yields encouraged us to prepare efficiently the natural stilbene **CA-4** by this way. Moreover, we also demonstrated that this hydrosilylation–protodesilylation sequence could be achieved in a one-pot way from various diarylalkynes.

Acknowledgements

The CNRS is gratefully acknowledged for financial support of this research and the MNSER for a doctoral fellowship to A.G.

References and notes

- (a) Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W. W.; Fong, H. H. S.; Farnworth, R. N.; Kinghorn, A. D.; Metha, R. G.; Moon, R. C.; Pezzuto, J. M. *Science* **1997**, *275*, 218; (b) Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettit, R. K. *J. Med. Chem.* **2005**, *48*, 4087 and references cited therein.
- (a) Pettit, G. R.; Cragg, G. M.; Singh, S. B. *J. Nat. Prod.* **1987**, *50*, 386; (b) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. *Experientia* **1989**, *45*, 209; (c) Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F. *J. Med. Chem.* **1995**, *38*, 1666.
- Ferré-Filmon, K.; Delaude, L.; Demonceau, A.; Noels, A. F. *Coord. Chem. Rev.* **2004**, *248*, 2323.
- (a) Lindlar, H. *Helv. Chim. Acta* **1952**, *35*, 446; (b) Lindlar, H.; Dubuis, R. *Org. Synth.* **1973**, *5*, 880.
- LeBras, G.; Radanyi, C.; Peyrat, J.-F.; Brion, J.-D.; Alami, M.; Marsaud, V.; Stella, B.; Renoir, J.-M. *J. Med. Chem.* **2007**, *50* <http://dx.doi.org/10.1021/jm0707774>.
- Provot, O.; Giraud, A.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. *Tetrahedron Lett.* **2005**, *46*, 8547.
- (a) Robinson, J. E.; Taylor, R. J. K. *Chem. Commun.* **2007**, 1617; (b) Harrowven, D. C.; Guy, I. L.; Howell, M.; Packham, G. *Synlett* **2006**, 2977; (c) Gaukroger, K.; Hadfield, J. A.; Hepworth, L. A.; Lawrence, N. J.; McGown, A. T. *J. Org. Chem.* **2001**, *66*, 8135; (d) Lawrence, N. J.; Abdul Ghani, F.; Hepworth, L. A.; Hadfield, J. A.; McGown, A. T.; Pritchard, R. G. *Synthesis* **1999**, 1656; (e) Fürstner, A.; Nikolakis, K. *Liebigs Ann.* **1996**, 2107.
- Lara-Ochoa, F.; Espinosa-Pérez, G. *Tetrahedron Lett.* **2007**, *48*, 7007.
- (a) Hamze, A.; Provot, O.; Brion, J.-D.; Alami, M. *Synthesis* **2007**, 2025; (b) Hamze, A.; Provot, O.; Alami, M.; Brion, J.-D. *Org. Lett.* **2005**, *7*, 5625.
- (a) Liron, F.; Le Garrec, P.; Alami, M. *Synlett* **1999**, 246; (b) Alami, M.; Liron, F.; Gervais, M.; Peyrat, J.-F.; Brion, J.-D. *Angew. Chem., Int. Ed.* **2002**, *41*, 1578; (c) Liron, F.; Gervais, M.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. *Tetrahedron Lett.* **2003**, *44*, 2789; (d) Bujard, M.; Ferri, F.; Alami, M. *Tetrahedron Lett.* **1998**, *39*, 4243; (e) Hamze, A.; Provot, O.; Brion, J.-D.; Alami, M. *J. Org. Chem.* **2007**, *72*, 3868.
- Dodd, D. E.; Stuart, B. O.; Rothenberg, S. J.; Kershaw, M.; Mann, P. C.; James, J. T.; Lam, C. W. *Inhal. Toxicol.* **1994**, *6*, 151.
- Speier's catalyst is well known to provide *cis*-addition processes for internal and terminal alkynes; see: Tsipis, C. A. *J. Organomet. Chem.* **1980**, *187*, 427.
- Procedure for the synthesis of CA-4*: In a 10 mL flask, PtO₂ (10 mg, 0.0035 mmol) and arylalkyne **1c** (0.5 mmol) were placed under nitrogen atmosphere. Dimethylethoxysilane (304 μL, 2 mmol) was introduced via syringe and the mixture was stirred at 60 °C in an oil bath for 1 h. The residue was concentrated and then purified by column chromatography over silica gel to yield the vinylsilanes as a mixture of regioisomers (147 mg; 70%). The mixture of vinylsilanes (147 mg, 0.35 mmol) was treated with TBAF in THF (1 mL, 1 N) at 60 °C for 1 h. After concentration in vacuo, the crude product was purified by column chromatography (SiO₂, cyclohexane/EtOAc: 70/30) to afford **CA-4** as a single *Z*-stereoisomer (75 mg; 69%). TLC: *R*_f 0.46 (cyclohexane/EtOAc: 70/30, 1/1, SiO₂). ¹H NMR (300 MHz, CDCl₃) δ 3.70 (s, 6H), 3.84 (s, 3H), 3.86 (s, 3H), 5.50 (br s, 1H, OH), 6.40 (d, 1H, *J* = 12.1 Hz), 6.47 (d, 1H, *J* = 12.1 Hz), 6.53 (s, 2H), 6.72 (d, 1H, *J* = 8.2 Hz), 6.80 (dd, 1H, *J* = 8.2 Hz, *J* = 1.8 Hz), 6.92 (d, 1H, *J* = 1.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ 55.9 (2C), 56.1, 60.9, 106.0 (2C), 110.3, 115.0, 121.1, 129.0, 129.5, 130.6, 132.7, 137.1, 145.2, 145.8, 152.8 (2C).
- Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. *J. Med. Chem.* **1991**, *34*, 2579.
- Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. *Mol. Pharmacol.* **1988**, *34*, 200.
- Maya, A. B.; Del Rey, B.; De Clairac, R. P.; Caballero, E.; Barasoain, I.; Andreu, J. M.; Medarde, M. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2549.